VILLA MATTEO

(2025). Investigation of drug resistance and co-mutational landscape of ALK-positive tumors. (Tesi di dottorato, , 2025). Detail

Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Detail

Malighetti, F., Villa, M., Sala, E., Geeta, G., Arosio, G., Gemelli, M., et al. (2024). Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy. Intervento presentato a: American Association for Cancer Research Annual Meeting 2024 - April 5-10, 2024, San Diego, CA [10.1158/1538-7445.am2024-987]. Detail

Villa, M., Geeta, G., Malighetti, F., Mauri, M., Arosio, G., Cordani, N., et al. (2024). Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. BRITISH JOURNAL OF CANCER, 131(11), 1781-1795 [10.1038/s41416-024-02881-7]. Detail

Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. LEUKEMIA, 38(8), 1843-1847 [10.1038/S41375-024-02282-Y]. Detail